title: Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
abstract: The PI3K/Akt and mTOR signaling pathways are important for cell survival and growth, and they are highly activated in cancer cells compared with normal cells. Therefore, these signaling pathways are targets for inducing cancer cell death. The dual PI3K/Akt and mTOR inhibitor NVP-BEZ235 completely inhibited both signaling pathways. However, NVP-BEZ235 had no effect on cell death in human renal carcinoma Caki cells. We tested whether combined treatment with natural compounds and NVP-BEZ235 could induce cell death. Among several chemopreventive agents, curcumin, a natural biologically active compound that is extracted from the rhizomes of Curcuma species, markedly induced apoptosis in NVP-BEZ235-treated cells. Co-treatment with curcumin and NVP-BEZ235 led to the down-regulation of Mcl-1 protein expression but not mRNA expression. Ectopic expression of Mcl-1 completely inhibited curcumin plus NVP-NEZ235-induced apoptosis. Furthermore, the down-regulation of Bcl-2 was involved in curcumin plus NVP-BEZ235-induced apoptosis. Curcumin or NVP-BEZ235 alone did not change Bcl-2 mRNA or protein expression, but co-treatment reduced Bcl-2 mRNA and protein expression. Combined treatment with NVP-BEZ235 and curcumin reduced Bcl-2 expression in wild-type p53 HCT116 human colon carcinoma cells but not p53-null HCT116 cells. Moreover, Bcl-2 expression was completely reversed by treatment with pifithrin-α, a p53-specific inhibitor. Ectopic expression of Bcl-2 also inhibited apoptosis in NVP-BE235 plus curcumin-treated cells. In contrast, NVP-BEZ235 combined with curcumin did not have a synergistic effect on normal human skin fibroblasts and normal human mesangial cells. Taken together, combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.
authors.affiliation: Department of Immunology, School of Medicine, Keimyung University, Daegu, South Korea.
authors.forename: Bo Ram
authors.initials: BR
authors.lastname: Seo
authors.affiliation: Department of Immunology, School of Medicine, Keimyung University, Daegu, South Korea.
authors.forename: Kyoung-Jin
authors.initials: KJ
authors.lastname: Min
authors.affiliation: College of Oriental Medicine, Daegu Haany University, Gyeongsan, Korea; Medical Research Center for Globalization of Herbal Formulation, Daegu Haany University, Gyeongsan, Korea.
authors.forename: Il Je
authors.initials: IJ
authors.lastname: Cho
authors.affiliation: College of Oriental Medicine, Daegu Haany University, Gyeongsan, Korea; Medical Research Center for Globalization of Herbal Formulation, Daegu Haany University, Gyeongsan, Korea.
authors.forename: Sang Chan
authors.initials: SC
authors.lastname: Kim
authors.affiliation: Department of Immunology, School of Medicine, Keimyung University, Daegu, South Korea.
authors.forename: Taeg Kyu
authors.initials: TK
authors.lastname: Kwon
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D003474:Curcumin / Q000494:pharmacology*; D053938:DNA Fragmentation / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D011804:Quinolines / Q000494:pharmacology*; D034741:RNA, Small Interfering; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D007093:Imidazoles; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011804:Quinolines; D034741:RNA, Small Interfering; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D003474:Curcumin; C531198:dactolisib
references.citation: Mol Nutr Food Res. 2014 Mar;58(3):516-27
references.pmid: 24402825
references.citation: Oncogene. 2002 May 30;21(24):3898-908
references.pmid: 12032828
references.citation: Cell Signal. 2006 Dec;18(12):2262-71
references.pmid: 16839745
references.citation: Oncogene. 2004 Jul 29;23(34):5853-7
references.pmid: 15208673
references.citation: Oncogene. 2005 Nov 14;24(50):7455-64
references.pmid: 16288292
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
references.pmid: 11504778
references.citation: Mol Cell Biol. 1996 Oct;16(10):5546-56
references.pmid: 8816467
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40
references.pmid: 12050094
references.citation: Mol Cell Biol. 1995 Jul;15(7):3840-7
references.pmid: 7791791
references.citation: Biochim Biophys Acta. 2014 Apr;1845(2):221-31
references.pmid: 24480319
references.citation: J Clin Oncol. 2009 May 1;27(13):2278-87
references.pmid: 19332717
references.citation: Cancer Biol Ther. 2011 Sep 15;12(6):549-55
references.pmid: 21738008
references.citation: Cancer Res. 2011 May 1;71(9):3246-56
references.pmid: 21430067
references.citation: Clin Cancer Res. 2008 Apr 1;14(7):2128-36
references.pmid: 18381954
references.citation: Carcinogenesis. 2005 Nov;26(11):1905-13
references.pmid: 15987718
references.citation: Cell. 2006 Oct 6;127(1):125-37
references.pmid: 16962653
references.citation: Clin Cancer Res. 2001 Oct;7(10):3269-75
references.pmid: 11595724
references.citation: Biochem Biophys Res Commun. 2001 Nov 2;288(3):658-65
references.pmid: 11676493
references.citation: Cancer Res. 2006 May 15;66(10):5130-42
references.pmid: 16707436
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):846-53
references.pmid: 12788194
references.citation: Trends Pharmacol Sci. 2009 Feb;30(2):85-94
references.pmid: 19110321
references.citation: Biochem Biophys Res Commun. 2008 Aug 8;372(4):578-83
references.pmid: 18505677
references.citation: Planta Med. 1998 May;64(4):353-6
references.pmid: 9619120
references.citation: EMBO J. 1988 Jan;7(1):123-31
references.pmid: 2834197
references.citation: Endocr Relat Cancer. 2001 Sep;8(3):237-48
references.pmid: 11566615
references.citation: Exp Cell Res. 2001 Dec 10;271(2):305-14
references.pmid: 11716543
references.citation: J Chemother. 2004 Nov;16 Suppl 4:3-6
references.pmid: 15688599
references.citation: Lung Cancer. 2006 Feb;51(2):181-91
references.pmid: 16324768
references.citation: Angew Chem Int Ed Engl. 2012 May 29;51(22):5308-32
references.pmid: 22566109
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304
references.pmid: 20007781
references.citation: Mol Cancer Ther. 2003 Jan;2(1):95-103
references.pmid: 12533677
references.citation: J Exp Ther Oncol. 2005;5(1):39-48
references.pmid: 16416600
references.citation: Cancer Res. 2007 Apr 15;67(8):3853-61
references.pmid: 17440100
references.citation: Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42
references.pmid: 19735878
references.citation: Anticancer Res. 2009 May;29(5):1739-43
references.pmid: 19443396
references.citation: Cancer Cell. 2005 Nov;8(5):381-92
references.pmid: 16286246
references.citation: Cell. 2005 Jul 1;121(7):1085-95
references.pmid: 15989957
references.citation: Clin Immunol. 1999 Nov;93(2):152-61
references.pmid: 10527691
references.citation: Mol Cell Endocrinol. 2012 Nov 25;364(1-2):101-4
references.pmid: 22960230
references.citation: BMC Complement Altern Med. 2006 Mar 17;6:10
references.pmid: 16545122
references.citation: Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8
references.pmid: 9990064
references.citation: Cancer Res. 1994 Jun 15;54(12):3131-5
references.pmid: 8205530
references.citation: Cancer Res. 2008 Oct 1;68(19):8022-30
references.pmid: 18829560
references.citation: Cancer Res. 2006 Feb 1;66(3):1500-8
references.pmid: 16452206
references.citation: Anticancer Res. 1999 Sep-Oct;19(5A):3675-80
references.pmid: 10625938
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Biochem J. 2007 Aug 1;405(3):513-22
references.pmid: 17461779
references.citation: Biochem Biophys Res Commun. 2003 Oct 31;310(4):1124-32
references.pmid: 14559232
references.citation: J Urol. 2007 Mar;177(3):899-902
references.pmid: 17296371
references.citation: Int J Biochem Cell Biol. 2003 May;35(5):606-16
references.pmid: 12672453
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Cell Death Dis. 2013 Feb 21;4:e505
references.pmid: 23429291
references.citation: Science. 2007 May 18;316(5827):1039-43
references.pmid: 17463250
references.citation: Oncogene. 2003 Sep 11;22(39):7891-9
references.pmid: 12970736
references.citation: Mol Cancer. 2011 Jul 26;10:90
references.pmid: 21791089
references.citation: Cancer Res. 2010 Oct 15;70(20):8097-107
references.pmid: 20876803
references.citation: J Biol Chem. 1997 Aug 1;272(31):19609-14
references.pmid: 9235968
references.citation: Oncol Rep. 2011 Nov;26(5):1273-9
references.pmid: 21725613
references.citation: Clin Cancer Res. 2010 Jul 15;16(14):3628-38
references.pmid: 20606035
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1851-63
references.pmid: 18606717
references.citation: Carcinogenesis. 2003 Jul;24(7):1199-208
references.pmid: 12807727
references.citation: Blood. 2010 Jan 21;115(3):559-69
references.pmid: 19965685
references.citation: Mol Cancer Ther. 2002 Oct;1(12):989-97
references.pmid: 12481421
references.citation: J Transl Med. 2011 Aug 11;9:133
references.pmid: 21834980
references.citation: Anticancer Res. 2001 Mar-Apr;21(2A):873-8
references.pmid: 11396178
references.citation: Cell. 2006 Feb 10;124(3):471-84
references.pmid: 16469695
references.citation: Blood. 2003 Feb 1;101(3):1053-62
references.pmid: 12393461